EFFECT OF FLUCONAZOLE ON THE DISPOSITION OF PHENYTOIN

被引:97
作者
BLUM, RA
WILTON, JH
HILLIGOSS, DM
GARDNER, MJ
HENRY, EB
HARRISON, NJ
SCHENTAG, JJ
机构
[1] PFIZER INC,PFIZER CENT RES,GROTON,CT 06340
[2] SUNY BUFFALO,CTR CLIN PHARM RES,BUFFALO,NY 14260
关键词
D O I
10.1038/clpt.1991.49
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In a randomized, placebo-controlled, parallel study, phenytoin was given in the presence and absence of fluconazole. Twenty healthy male subjects received phenytoin, 200 mg orally, on study days 1 to 3 and 18 to 20 and 250 mg intravenously on study days 4 and 21. Ten subjects received fluconazole, 200 mg orally, and 10 received placebo daily on study days 8 to 21. Serial blood samples were collected during a 24-hour period after the intravenous phenytoin dose. Fluconazole trough concentrations were determined on days 14, 18, and 21. Serum phenytoin area under the concentration-time curve from 0 to 24 hours increased 75% and minimum plasma drug concentration increased 128% after administration of fluconazole, 200 mg/day, for 14 days. These values were significantly greater than the 5% increase in area under the concentration-time curve from 0 to 24 hours and 11.6% increase in minimum plasma drug concentration in the placebo group. Fluconazole trough concentrations remained unchanged during the coadministration of phenytoin. The increased phenytoin concentrations in the presence of fluconazole suggest that fluconazole inhibits phenytoin metabolism. Serum concentration monitoring with a reduction in phenytoin dosage is clinically warranted in patients receiving phenytoin and concomitant fluconazole therapy.
引用
收藏
页码:420 / 425
页数:6
相关论文
共 20 条
  • [1] UTILIZATION OF KM FOR PHENYTOIN DOSAGE AFTER FOLATE ADDITION TO PATIENT REGIMEN
    BERG, MJ
    EBERT, BE
    RIVEY, MP
    SCHOTTELIUS, DD
    [J]. THERAPEUTIC DRUG MONITORING, 1987, 9 (03) : 304 - 305
  • [2] DISPOSITION OF KETOCONAZOLE, AN ORAL ANTIFUNGAL, IN HUMANS
    BRASS, C
    GALGIANI, JN
    BLASCHKE, TF
    DEFELICE, R
    OREILLY, RA
    STEVENS, DA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1982, 21 (01) : 151 - 158
  • [3] EFFECT OF KETOCONAZOLE ON HEPATIC OXIDATIVE DRUG-METABOLISM
    BROWN, MW
    MALDONADO, AL
    MEREDITH, CG
    SPEEG, KV
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (03) : 290 - 297
  • [4] CRYPTOCOCCAL MENINGITIS IN THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) - SUCCESSFUL TREATMENT WITH FLUCONAZOLE AFTER FAILURE OF AMPHOTERICIN-B
    BYRNE, WR
    WAJSZCZUK, CP
    [J]. ANNALS OF INTERNAL MEDICINE, 1988, 108 (03) : 384 - 385
  • [5] DELFA IL, 1989, DRUG METAB DISPOS, V17, P49
  • [6] Dupont B, 1988, Ann N Y Acad Sci, V544, P564, DOI 10.1111/j.1749-6632.1988.tb40453.x
  • [7] CRYPTOCOCCAL MENINGITIS AND FLUCONAZOLE
    DUPONT, B
    DROUHET, E
    [J]. ANNALS OF INTERNAL MEDICINE, 1987, 106 (05) : 778 - 778
  • [8] FLUCONAZOLE PENETRATION INTO CEREBROSPINAL-FLUID IN HUMANS
    FOULDS, G
    BRENNAN, DR
    WAJSZCZUK, C
    CATANZARO, A
    GARG, DC
    KNOPF, W
    RINALDI, M
    WEIDLER, DJ
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 28 (04) : 363 - 366
  • [9] Foulds G, 1988, Ann N Y Acad Sci, V544, P427, DOI 10.1111/j.1749-6632.1988.tb40440.x
  • [10] EFFECTS OF KETOCONAZOLE ON METHYLPREDNISOLONE PHARMACOKINETICS AND CORTISOL SECRETION
    GLYNN, AM
    SLAUGHTER, RL
    BRASS, C
    DAMBROSIO, R
    JUSKO, WJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 39 (06) : 654 - 659